Source-grounded facts extracted from INTEST CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INTEST CORP reported first quarter of 2026 ended March 31, 2026 results: revenue $33.9 Million, net income $0.8 million, EPS $0.06. Guidance raised.
“InTest Reports Strong First Quarter 2026 Revenue of $33.9 Million EPS of $0.06 and Adjusted EPS (Non-GAAP) of $0.16”
INTEST CORP entered into Purchase Agreement with Mauro Arigossi; Elettra S.S. valued at approximately €20 million (effective 2024-03-12).
“On March 12, 2024 inTEST Corporation (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) by and among inTEST Italy, Inc., a wholly owned subsidiary of the Company (“Buyer”), Mauro Arigossi (“Arigossi”), and Elettra S.S., a company incorporated under the Laws of Italy (“Elettra”, and together with Arigossi, each a “Seller” and collectively, the “Sellers”).”
INTEST CORP reported first quarter ended March 31, 2024 results: revenue $29.8 Million, EPS $0.05. Guidance reaffirmed.
“inTEST Reports $29.8 Million in Revenue for First Quarter 2024”
INTEST CORP amended credit facility with M&T Bank maturing May 2, 2031.
“the term loan and revolving credit facility maturity date is extended from September 19, 2027 to May 2, 2031.”
INTEST CORP reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 27, 2024, inTEST Corporation (the "Company") issued a press release regarding its financial results for the fourth quarter and year ended December 31, 2023.”
INTEST CORP completed an acquisition involving Mauro Arigossi and Elettra S.S. for approximately €20 million (closed 2024-03-12).
“all of the outstanding capital shares of Alfamation. Pursuant to the Purchase Agreement, the Buyer agreed to pay to the Sellers an aggregate base purchase price of approximately €20 million comprised of: (i) approximately €18 million in cash; and (ii) 187,432 shares of common stock of the Company, par value $0.01 (the “Shares”); and an additional approximately €542”
INTEST CORP entered into Lease Agreement with Elettra Real Estate S.r.l valued at €231,312 (effective 2024-03-12).
“In connection with the Purchase Agreement, Alfamation has entered into a lease agreement (the “Lease Agreement”) by and between Alfamation and Elettra Real Estate S.r.l , a limited liability company incorporated under the Laws of Italy (the “Landlord”).”
INTEST CORP entered into Purchase Agreement with Mauro Arigossi and Elettra S.S. valued at approximately €20 million (effective 2024-03-12).
“On March 12, 2024 inTEST Corporation (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) by and among inTEST Italy, Inc., a wholly owned subsidiary of the Company (“Buyer”), Mauro Arigossi (“Arigossi”), and Elettra S.S., a company incorporated under the Laws of Italy (“Elettra”, and together with Arigossi, each a “Seller” and collectively, the “Sellers”).”
INTEST CORP reported that prior financial statements should not be relied upon.
“should no longer be relied upon due to certain errors identified by the Company.”
INTEST CORP reported full year 2024 results: revenue in the range of $125 million to $130 million. Guidance initiated.
“Revenue for full year 2024 is expected to be in the range of $125 million to $130 million.”
INTEST CORP reported the first quarter of 2024 results: revenue in the range of $28 million to $30 million, EPS in the range of $0.08 to $0.13. Guidance initiated.
“Revenue for the first quarter of 2024 is expected to be in the range of $28 million to $30 million with gross margin of approximately 46%. First quarter 2024 earnings per diluted share is expected to be in the range of $0.08 to $0.13.”
INTEST CORP reported the fourth quarter ended December 31, 2023 results: revenue approximately $28.4 million, net income approximately $1.7 million, EPS $0.14 per diluted share.
“Fourth quarter 2023 revenue was approximately $28.4 million with net earnings of approximately $1.7 million, or $0.14 per diluted share.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.